Unknown

Dataset Information

0

Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial.


ABSTRACT:

Background

Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.

Objective

We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.

Methods

We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).

Results

The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).

Conclusions

We will disseminate the results in a peer-reviewed journal.

Trial registration

ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).

International registered report identifier (irrid)

DERR1-10.2196/11911.

SUBMITTER: Kromer C 

PROVIDER: S-EPMC6329412 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial.

Kromer Christian C   Nühnen Viktoria P VP   Pfützner Wolfgang W   Pfeiffer Sebastian S   Laubach Hans-Joachim HJ   Boehncke Wolf-Henning WH   Liebmann Joerg J   Born Matthias M   Schön Michael P MP   Buhl Timo T  

JMIR research protocols 20190108 1


<h4>Background</h4>Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.<h4>Objective</h4>We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for  ...[more]

Similar Datasets

| S-EPMC5216177 | biostudies-literature
| S-EPMC9804170 | biostudies-literature
| S-EPMC8290589 | biostudies-literature
| S-EPMC5389157 | biostudies-literature
| S-EPMC7503766 | biostudies-literature
2009-10-31 | E-GEOD-16161 | biostudies-arrayexpress
2025-09-10 | GSE225779 | GEO
2022-10-24 | GSE208669 | GEO
| S-EPMC2883413 | biostudies-literature
| S-EPMC4222770 | biostudies-literature